Cordycepin inhibits kidney injury by regulating GSK-3β-mediated Nrf2 activation

Zhiling Tang1, Kean Chen1, Chun Sun1

  • 1Department of Urology Surgery, The Second Affiliated Hospital of Jiaxing University, Zhejiang, China.

Insights

Cordycepin (COR) protects against cisplatin-induced kidney injury by inhibiting ferroptosis. This effect is mediated through glycogen synthase kinase-3 beta (GSK-3β), revealing a new therapeutic target for kidney damage.

Area of Science:

  • Pharmacology
  • Nephrology
  • Biochemistry

Background:

  • Kidney injury is a significant clinical challenge.
  • Cisplatin (CDDP) is a common chemotherapeutic agent that causes kidney damage.
  • Ferroptosis, a form of regulated cell death, plays a role in kidney injury.

Purpose of the Study:

  • To investigate the protective role of cordycepin (COR) against kidney injury.
  • To elucidate the mechanism underlying COR's protective effects, focusing on ferroptosis.
  • To identify the molecular targets of COR in kidney injury.

Main Methods:

  • A mouse model of cisplatin-induced kidney injury was established.
  • Kidney function, histopathology, and ferroptosis markers were assessed.
  • Network pharmacology was used to predict COR targets.
  • In vitro studies using HK-2 cells were performed to validate findings.

Main Results:

  • Cordycepin (COR) administration ameliorated cisplatin (CDDP)-induced kidney injury in mice.
  • COR inhibited ferroptosis in both in vivo and in vitro models.
  • Network pharmacology identified glycogen synthase kinase-3 beta (GSK-3β) as a key target of COR.
  • Inhibition of GSK-3β abolished the ferroptosis-inhibitory effect of COR.

Conclusions:

  • Cordycepin (COR) exerts protective effects against CDDP-induced kidney injury.
  • The mechanism involves the inhibition of ferroptosis via GSK-3β signaling.
  • GSK-3β is a novel therapeutic target for COR in kidney injury treatment.